Abstract: Disclosed are methods for inhibiting the progression of neurodegenerative disease. The methods include administering to a patient suffering from such a disease a composition comprising either deuterated linoleic acid or an ester thereof.

Abstract: Methods for preparing isotopically modified 1,4-diene systems from non-isotopically modified 1,4-dienes involve selective oxidation of one or more bis-allylic position(s), or the preparation of isotopically modified 1,4-diene systems via trapping pi-allylic complexes with a source of deuterium or tritium. Such methods are useful for preparing isotopically modified polyunsaturated lipid including polyunsaturated fatty acids and polyunsaturated fatty acid derivatives.

Abstract: Disclosed are uses of isotopically modified polyunsaturated compounds for treating, ameliorating or inhibiting the progression of a neurodegenerative disease or condition related to tauopathy in a subject in need thereof. In certain embodiments, the isotopically modified polyunsaturated compounds are deuterated polyunsaturated fatty acids or derivatives thereof.

Abstract: Disclosed are methods for inhibiting the progression of oxidative retinal diseases. The methods include administration of deuterated docosahexaenoic acid or an ester thereof to a patient in need thereof.

Abstract: Disclosed herein are compositions and methods for controlling chronic inflammation in a patient. The compositions and methods employ D6-arachidonic acid or an ester thereof (D6-AA) as an anti-inflammatory agent that provides for significant reduction in inflammatory processes. In addition. The compositions of deuterated arachidonic acid or ester thereof comprise, on average, at least about 80% of the hydrogen atoms at each of the bis-allylic sites having been replaced by deuterium atoms and, on average, no more than about 30% of the hydrogen atoms at the mono-allylic sites having been replaced by deuterium atoms.

Abstract: Disclosed herein are methods of treating or inhibiting the progression of inflammatory diseases, comprising administering an effective amount of a polyunsaturated substance to a patient having inflammation and in need of treatment, wherein the polyunsaturated substance is chemically modified such that one or more bonds are stabilized against oxidation. More specifically, the present disclosure provides methods for treating, reducing, or preventing inflammatory conditions by administering to a subject compositions comprising essential polyunsaturated fatty acids (PUFAs) and derivatives thereof having site-specific isotopic modifications at one or more “bis-allylic” (a CH2 group found between two alkene fragments) and/or at one or more “pro-bis-allylic” (a methylene group that become a bis-allylic position upon desaturation) positions.

Abstract: Some aspects of the invention provide for a method of treating hepatic disorders, lipidemias and cardiac-related risk factors using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds.

Abstract: Disclosed are methods for inhibiting the progression of amyotrophic lateral sclerosis (ALS) in humans. The methods use a synergistic combination of 3-methyl-1-phenyl-2-pyrazoline-5-one and deuterated arachidonic acid or a prodrug thereof, such as 11,11-D2-linoleic acid or an ester thereof.

Abstract: Methods for preparing isotopically modified 1,4-diene systems from non-isotopically modified 1,4-dienes involve selective oxidation of one or more bis-allylic position(s), or the preparation of isotopically modified 1,4-diene systems via trapping pi-allylic complexes with a source of deuterium or tritium. Such methods are useful for preparing isotopically modified polyunsaturated lipid including polyunsaturated fatty acids and polyunsaturated fatty acid derivatives.

Abstract: Isotopically modified polyunsaturated fatty acid or ester thereof, such as 11,11-D2-linoleic acid or its ethyl ester, and uses of the same for treating or ameliorating the symptoms of Friedreich's ataxia are disclosed.

Abstract: Disclosed herein are methods for preparing isotopically modified polyunsaturated lipids containing 1,4-diene systems involving selective isotopic modification of one or more bis-allylic positions of the polyunsaturated lipids in the presence of a transition metal catalyst.

Abstract: Disclosed herein are methods for preparing isotopically modified polyunsaturated lipids containing 1,4-diene systems involving selective isotopic modification of one or more bis-allylic positions of the polyunsaturated lipids in the presence of a transition metal catalyst.